http://www.inhibitortargets.com/index.php/2017/09/30/ratio-non-synonymous-substitutions-rate-synonymous-substitutions/ 2022-01-14T05:07:34+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/09/28/present-study-potato-pi6c-potato-genotypes/ 2022-01-14T05:07:34+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/09/26/cysteine-residues-amino-acid-residue-array-reaction-centres/ 2022-01-14T05:07:34+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/09/25/c5-cysteine-residue-predicted-form-disulphide-bridge-adjacent/ 2022-01-14T05:07:34+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/09/24/pyronin-related-compound-mc-002595-pabn-methods-fluorescence/ 2022-01-14T05:07:34+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/09/21/multidrug-efflux-pumps-resistance-nodulation-cell-division-family-pumps/ 2022-01-14T05:07:34+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/09/20/excluding-systemic-effects-probable-binding-modes/ 2022-01-14T05:07:34+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/09/19/gain-activity-17b-hsd1-selectivity-17b-hsd2/ 2022-01-14T05:07:34+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/09/18/data-orientation-amide-group-important-feature/ 2022-01-14T05:07:34+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/09/17/inhibitors-6-21-crystal-structures-examined/ 2022-01-14T05:07:35+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/09/15/promising-17b-hsd1-inhibitors-optimizing-silico-identified-core-scaffold/ 2022-01-14T04:38:39+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/09/13/adjuvant-treatment-breast-cancer-active-inhibitor-17b-hsd1/ 2022-01-14T04:38:39+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/09/12/its-action-either-via-transactivation-of-estrogen-receptors-by-stimulating-nongenomic-effects/ 2022-01-14T04:38:39+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/09/11/induced-a-dose-dependent-down-regulation-of-p53-for-the-treatment-of-edd/ 2022-01-14T04:38:39+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/09/10/agent-and-vinorelbine-a-microtubule-depolymerising-agent/ 2022-01-14T04:38:39+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/09/08/in-the-present-study-we-found-that-in-contrast-to-saha-novel-hdaci-inhibit/ 2022-01-14T04:38:40+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/09/07/to-explore-the-cellularmolecular-basis-of-the-interaction-between-paclitaxel/ 2022-01-14T04:38:40+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/09/05/epigenetic-modifications-and-deregulation-the-rate-of-its-inhibition/ 2022-01-14T04:38:40+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/09/04/many-proteins-are-specifically-produced-in-the-male-urogenital-tract/ 2022-01-14T04:38:40+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/09/03/these-results-may-be-explained-by-the-possibility-that-n-linked-glycans/ 2022-01-14T04:38:40+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/08/31/differences-in-sialylated-n-glycans-nor-to-the-high-mannose-structures-observed/ 2022-01-14T04:38:40+00:00 daily 0.9